Cysteine effects on the pharmacokinetics of etoposide in protein-calorie malnutrition rats: Increased gastrointestinal absorption by cysteine

Xenobiotica

Volumn 41, Issue 10, 2011, Pages 885-894

  Suh, J H ^a   Kang, H E ^b   Yoon, I S ^a   Yang, S H ^c   Kim, S H ^d   Lee, H J ^e   Shim, C K ^a   Lee, M G ^a,b  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Gangneung Wonju National University   (South Korea)

^e Bio Medical Research Center   (South Korea)

Author keywords

CYP; cysteine; Etoposide; P gp; pharmacokinetics; protein calorie malnutrition

Indexed keywords

CYSTEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; ETOPOSIDE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE MUCOSA PERMEABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN CALORIE MALNUTRITION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYSTEINE; CYTOCHROME P-450 CYP3A; EATING; ETOPOSIDE; GASTROINTESTINAL TRACT; INTESTINAL ABSORPTION; MALE; PERMEABILITY; PROTEIN-ENERGY MALNUTRITION; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

RATTUS;

EID: 80052906137     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.585186     Document Type: Article

References (43)

1. Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. (2009).Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol 156:1019-1028.
2. al-Shawi MK, Urbatsch IL, Senior AE. (1994).Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 269:8986-8992.
3. Bae SK, Lee SJ, Kwon JW, Kim WB, Lee MG. (2004).Effects of roteincalorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. J Pharm Pharmacol 56:635-642. (Pubitemid 38607655)
4. Boullata JI. (2010).Drug disposition in obesity and protein-energy malnutrition. Proc Nutr Soc 69:543-550.
5. Buchanan N. (1978).Drug kinetics in protein energy malnutrition. S Afr Med J 53:327-330. (Pubitemid 8310868)
6. Chiou WL. (1978).Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
7. Cho MK, Kim YG, Lee MG, Kim SG. (1999).Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 372:150-158.
8. Choi YH, Kim SG, Lee MG. (2006).Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543-2552. (Pubitemid 44726394)
9. Clark PI, Slevin ML. (1987).The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223-252. (Pubitemid 17072058)
10. Denke M, Wilson JD. (1998).Protein and energy malnutrition. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. Principles of Internal Medicine (14th edn).New York: McGraw-Hill, 452-454.
11. Föer F, Schmitz T, Bernkop-Schnürch A. (2006).In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27:4250-4255.
12. Gamelli RL, Foster RS Jr. (1983).Effects of protein-calorie malnutrition and refeeding on fluorouracil toxicity. Arch Surg 118:1182-1185. (Pubitemid 13005832)
13. Gibaldi M, Perrier D, eds. (1982).Pharmacokinetics (2nd edn).New York: Marcel-Dekker.
14. Gonzalez-Hernandez I, Jung-Cook H, Sotelo A. (2008).Effect of malnutrition on the pharmacokinetics of cefuroxime axetil in young rats. J Pharm Pharm Sci 11:9-21.
15. Guo A, Marinaro W, Hu P, Sinko PJ. (2002).Delineating the contribution of secretory transporters in the efflux of etoposide using Madin- Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).Drug Metab Dispos 30:457-463. (Pubitemid 34263832)
16. Hande K, Anthony L, Hamilton R, Bennett R, Sweetman B, Branch R. (1988a).Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res 48:1829-1834.
17. Hande K, Bennett R, Hamilton R, Grote T, Branch R. (1988b).Metabolism and excretion of etoposide in isolated, perfused rat liver models. Cancer Res 48:5692-5695.
18. Hong H, Lu Y, Ji ZN, Liu GQ. (2006).Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J Neurochem 98:1465-1473. (Pubitemid 44200438)
19. Kaminsky LS, Fasco MJ. (1991).Small intestinal cytochromes P450. Crit Rev Toxicol 21:407-422.
20. Kaminsky LS, Zhang QY. (2003).The small intestine as a xenobioticmetabolizing organ. Drug Metab Dispos 31:1520-1525.
21. Kim SH, Choi YM, Lee MG. (1993).Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17. (Pubitemid 23261727)
22. Kim MK, Han L, Choi MK, Han YH, Kim DD, Chung SJ, Shim CK. (2005).Dose dependency in the oral bioavailability of an organic cation model, tributylmethyl ammonium (TBuMA), in rats: association with the saturation of efflux by the P-gp system on the apical membrane of the intestinal epithelium. J Pharm Sci 94:2644-2655. (Pubitemid 43265388)
23. Krishnaswamy K. (1978).Drug metabolism and pharmacokinetics in malnutrition. Clin Pharmacokinet 3:216-240. (Pubitemid 8333337)
24. Lagas JS, Fan L, Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH, Schinkel AH. (2010).P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 16:130-140.
25. Lee MG, Chiou WL. (1983).Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640. (Pubitemid 14070321)
26. Lee YM, Song IS, Kim SG, Lee MG, Chung SJ, Shim CK. (2003).The suppressed expression and functional activity of hepatic P-glycoprotein in rats with protein-calorie malnutrition. J Pharm Sci 92:1323-1330. (Pubitemid 36792746)
27. Lee JH, Suh OK, Lee MG. (2004).Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res 27:693-712.
28. Lee DY, Lee I, Lee MG. (2007).Effects of cysteine on the pharmacokinetic parameters of omeprazole in rats with proteincalorie malnutrition: partial restoration of some parameters to control levels by oral cysteine supplementation. JPEN J Parenter Enteral Nutr 31:37-46. (Pubitemid 46036296)
29. Leu BL, Huang JD. (1995).Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432-436.
30. Li X, Yun JK, Choi JS. (2007).Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 28:151-156. (Pubitemid 46730923)
31. Li C, Li X, Choi JS. (2009).Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats. Arch Pharm Res 32:133-138.
32. Lowry SF, Goodgame JT Jr, Norton JA, Jones DC, Brennan MF. (1977).Effect of protein malnutrition on host-tumor composition and growth. Surg Forum 28:143-145.
33. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. (1998). Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15:1160-1167. (Pubitemid 28401704)
34. Martignoni M, Groothuis G, de Kanter R. (2006).Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 34:1047-1054. (Pubitemid 43763764)
35. Murakami T, Nakanishi M, Yoshimori T, Okamura N, Norikura R, Mizojiri K. (2003).Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18:252-260.
36. Obama M, Cangir A, van Eys J. (1983).Nutritional status and anthracycline cardiotoxicity in children. South Med J 76:577-578. (Pubitemid 13099852)
37. Piao YJ, Li X, Choi JS. (2008).Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats. Eur J Drug Metab Pharmacokinet 33:159-164.
38. Senthilkumari S, Velpandian T, Biswas NR, Saxena R, Ghose S. (2008).Evaluation of the modulation of P-glycoprotein (P-gp) on the intraocular disposition of its substrate in rabbits. Curr Eye Res 33:333-343. (Pubitemid 351507755)
39. Sezer S, Ibis A, Ozdemir BH, Ozdemir FN, Kulah E, Boyacioglu S, Haberal M. (2004). Association of helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc 36:47-49. (Pubitemid 38177185)
40. Shirazi FH, Bahrami G, Stewart DJ, Tomiak E, Delorme F, Noel D, Goel R. (2001).A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. J Pharm Biomed Anal 25:353-356. (Pubitemid 32493890)
41. Walker O, Dawodu AH, Salako LA, Alván G, Johnson AO. (1987).Single dose disposition of chloroquine in kwashiorkor and normal children-evidence for decreased absorption in kwashiorkor. Br J Clin Pharmacol 23:467-472. (Pubitemid 17108179)
42. Werle M, Hoffer M. (2006).Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release 111:41-46. (Pubitemid 43289993)
43. Wilkinson GR, Shand DG. (1975).A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.